JERSEY CITY, N.J., Dec. 17, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that the company recently conducted its Clinical Trial Transparency Leadership Forum, part of TrialScope's Transparency Leadership Series which is designed to bring leaders in life sciences companies together to discuss and debate current and emerging clinical trial transparency and compliance topics.
Each of the Forum programs are developed around specific topics or themes that are timely and important to compliance leaders. The December Forum included discussions of global disclosure performance and was highlighted by a presentation by Jennifer Miller, PhD. Assistant Professor, Division of Medical Ethics, NYU School of Medicine's Department of Population Health and President of Bioethics International entitled, "The Good Pharma Scorecard". Thomas Wicks, Chief Strategy Officer at TrialScope also presented findings from TrialScope's Clinical Trial Disclosure Maturity Model. The presentations and ensuing discussions highlighted the importance of measuring disclosure performance as well as the marketplace perception of such performance while also noting the challenges that most life sciences companies face when developing global disclosure policies.
Mike Forgash, CEO, TrialScope, commented, "TrialScope's Transparency Leadership Forum was an exceptional event that enabled industry leaders to step away from their desks and talk about important strategic and operational topics that impact clinical trial transparency programs with industry peers. The program is founded on the idea that these leaders can share their rationales, best practices, and challenges in an intimate setting with the goal of learning and improving existing disclosure performance."
Thomas Wicks, Chief Strategy Officer, noted, "The Transparency Leadership Series provides a unique opportunity for our industry peers to collaborate in a non-competitive environment. We purposely design plenty of discussion time into the program so participants get maximum value from their time together. In this Forum, we addressed disclosure performance as a collection of important metrics that tell a sponsor's compliance story. We also heard the concern about how that story is viewed by the market and the potential impact it has on brand integrity. We plan to offer similar programs in the New Year and will look to current participants to help us shape the agenda and prioritize discussion topics."
About TrialScope
TrialScope simplifies the complexities of clinical transparency management. TrialScope is a proven solution that has been implemented successfully and rigorously tested in the most complex environments with solutions that are currently implemented at 13 of the top 30 global clinical trial sponsors, including 6 of the top 10. The company's market-driven solutions and expertise enable sponsors to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater compliance. TrialScope technology is offered via a validation-ready SaaS platform hosted in a private cloud.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.